Clearmind reaches 20 patients dosed in CMND-100 alcohol use disorder trial

Clearmind Medicine Inc. (CMND) — Clearmind Medicine said two more patients were dosed in the fourth cohort of its FDA-cleared Phase 1/2a trial of CMND-100 (MEAI) for moderate-to-severe alcohol use disorder, bringing the total treated to 20 across all cohorts.

The fourth cohort uses a higher 160 mg dose following a positive safety-monitoring-board recommendation, and the newest patients were treated at Hadassah Medical Center in Jerusalem. The update marks steady enrollment progress for the microcap's lead non-hallucinogenic program.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.